APTO Company Profile and Key Details
Aptose Biosciences
Price Chart
Stock Price Today
Aptose Biosciences Inc. (APTO) stock surged +100.00%, trading at $1.71 on NASDAQ, up from the previous close of $1.71. The stock opened at $1.71, fluctuating between $1.71 and $1.71 in the recent session.
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 10, 2026 | 0.00 | 1.71 | 0.00 | 1.71 | 648.21K |
| Apr 01, 2025 | 1.99 | 1.99 | 1.35 | 1.71 | 651.06K |
| Mar 31, 2025 | 3.30 | 3.43 | 3.14 | 3.15 | 29.06K |
| Mar 28, 2025 | 3.32 | 3.38 | 3.21 | 3.32 | 32.06K |
| Mar 27, 2025 | 3.35 | 3.76 | 3.35 | 3.70 | 17.12K |
| Mar 26, 2025 | 3.56 | 3.56 | 3.40 | 3.49 | 10.1K |
| Mar 25, 2025 | 3.57 | 3.68 | 3.20 | 3.48 | 64.72K |
| Mar 24, 2025 | 3.65 | 3.77 | 3.45 | 3.56 | 20.11K |
| Mar 21, 2025 | 3.89 | 3.95 | 3.37 | 3.69 | 43.51K |
| Mar 20, 2025 | 3.85 | 3.95 | 3.70 | 3.93 | 8.34K |
| Mar 19, 2025 | 3.75 | 3.93 | 3.68 | 3.81 | 9.95K |
| Mar 18, 2025 | 3.69 | 3.98 | 3.63 | 3.76 | 12.99K |
| Mar 17, 2025 | 3.92 | 3.92 | 3.56 | 3.79 | 20.12K |
| Mar 14, 2025 | 3.78 | 3.85 | 3.63 | 3.69 | 16.9K |
| Mar 13, 2025 | 3.69 | 3.86 | 3.50 | 3.78 | 26.71K |
| Mar 12, 2025 | 3.41 | 3.55 | 3.25 | 3.48 | 11.3K |
| Mar 11, 2025 | 3.44 | 3.53 | 3.11 | 3.41 | 18.8K |
| Mar 10, 2025 | 3.12 | 3.44 | 3.11 | 3.35 | 45.16K |
| Mar 07, 2025 | 2.94 | 3.17 | 2.82 | 3.17 | 17.61K |
| Mar 06, 2025 | 3.03 | 3.16 | 2.85 | 2.95 | 29.92K |
Contact Details
About Company
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Company Information
| Employees | 35 |
| Beta | 1.13 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Vice President of Fin.
Mr. Roger Davies B.Sc.
Vice President of Operations
Mr. Philippe Ledru
Senior Vice President & Chief Commercial Officer
Dr. Rafael Bejar M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Dr. William G. Rice Ph.D.
Chairman, Pres, Chief Executive Officer & Chief Accounting Officer
Dr. Marc Wiles Ph.D.
Senior Vice President of Regulatory Affairs
Mr. Brooks Ensign M.B.A.
Vice President & Controller
Mr. Fletcher Payne
Senior Vice President, Chief Financial Officer & Sec.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep